Compare VRA & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRA | CNTB |
|---|---|---|
| Founded | 1982 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.6M | 140.4M |
| IPO Year | 2010 | 2020 |
| Metric | VRA | CNTB |
|---|---|---|
| Price | $7.53 | $0.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 474.4K | ★ 1.0M |
| Earning Date | 12-10-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.47 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $416,097,000.00 | $64,000.00 |
| Revenue This Year | N/A | $11,287.85 |
| Revenue Next Year | $3.56 | $74.11 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.39 | $0.73 |
| 52 Week High | $7.13 | $3.82 |
| Indicator | VRA | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 81.50 | 35.59 |
| Support Level | $3.05 | $0.73 |
| Resistance Level | N/A | $2.62 |
| Average True Range (ATR) | 0.35 | 0.06 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 90.97 | 9.31 |
Vera Bradley Inc designs women's handbags, luggage, and travel items, fashion and home accessories, and gifts. Each category comprises a substantial component of total sales, with the bags category comprising the majority of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct and Vera Bradley Indirect.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.